GOOGLE SCHOLAR: https://scholar.google.co.in/citations?user=PnM5oyUAAAAJ&hl=en
RESEARCH GATE: https://www.researchgate.net/profile/Lalima-K-Madan
FIGURE 6: Structural comparison of F225 equivalent position in PTP1B and SHP2.
Top panels show the overall domain architecture of PTP1B (left) and SHP2 (right). PTP1B consists of a single catalytic PTP domain, while SHP2 contains two N-terminal SH2 domains (N-SH2 in purple, C-SH2 in light green) in addition to the PTP catalytic domain (cyan). C215 (PTP1B) and C459 (SHP2) in the active site are shown in yellow at equivalent positions. Bottom panels show a detailed view of the aromatic cluster surrounding F225/F469 in WPD-open conformations. Left: PTP1B showing F225 (green, asterisk) in static “down” conformation, forming an aromatic network with F191 and F194, with catalytic cysteine C215 (yellow) and catalytic aspartate D181. Right: SHP2 showing F469 (cyan, asterisk) at the equivalent position with V435 replacing F191, F438 corresponding to F194, catalytic C459 (yellow), and catalytic D425. Despite similar local architecture, F469 exhibits conformational flexibility (dual occupancy) not observed in PTP1B F225, indicating subfamily-specific regulatory mechanisms. This distinct conformational behavior at equivalent positions may provide a structural basis for designing subfamily-selective allosteric inhibitors that could differentially target PTP1B for diabetes versus SHP2 for cancer.
Proc Natl Acad Sci U S A 2019 Jul 23;116(30):15052-15061. PMID: 31285328 PMCID: PMC6660753
IUBMB Life 2019 Jun;71(6):685-696. PMID: 31063633 PMCID: PMC6690483
Proc Natl Acad Sci U S A 2017 Feb 7;114(6):E931-E940. PMID: 28115705 PMCID: PMC5307475
Biochemistry 2011 Nov 22;50(46):10114-25. PMID: 22007620 PMCID: PMC3667199
© MadanLaboratory.com